Baseline characteristics and early on-treatment response predict the outcomes of 2 years of telbivudine treatment of chronic hepatitis B

بواسطة Zeuzem, S., Gane, E., Liaw, Y.-F., Lim, S.G., DiBisceglie, A., Buti, M., Chutaputti, A., Rasenack, J., Hou, J., O'Brien, C., Nguyen, T.T., Jia, J., Poynard, T., Belanger, B., Bao, W., Naoumov, N.V.
منشور في 2016

Randomized trial of albinterferon alfa-2b every 4 weeks for chronic hepatitis C virus genotype 2/3

بواسطة Pianko S., Zeuzem S., Chuang W.-L., Foster G.R., Sarin S.K., Flisiak R., Lee C.-M., Andreone P., Piratvisuth T., Shah S., Sood A., George J., Gould M., Komolmit P., Thongsawat S., Tanwandee T., Rasenack J., Li Y., Pang M., Yin Y., Feutren G., Jacobson I.M.
منشور في 2014

Randomized trial of albinterferon alfa-2b every 4 weeks for chronic hepatitis C virus genotype 2/3

بواسطة Pianko S., Zeuzem S., Chuang WL., Foster GR., Sarin SK., Flisiak R., Lee CM., Andreone P., Piratvisuth T., Shah S., Sood A., George J., Gould M., Komolmit P., Thongsawat S., Tanwandee T., Rasenack J., Li Y., Pang M., Yin Y., Feutren G., Jacobson IM., for the B2202 Study Team.
منشور في 2014